Avandamet OK to use first

July 17, 2006

Prescribing physicians will now be able to initiate treatment for Type 2 diabetes with GlaxoSmithKline's Avandamet, a combination product containing both rosiglitazone maleate and metformin HCl, following a recent approval by the FDA. Previously, the drug was approved only as a second-line therapy in patients whose diabetes was uncontrolled on metformin alone.

Avandamet OK to use first

Prescribing physicians will now be able to initiate treatment for Type 2 diabetes with GlaxoSmithKline's Avandamet, a combination product containing both rosiglitazone maleate and metformin HCl, following a recent approval by the FDA. Previously, the drug was approved only as a second-line therapy in patients whose diabetes was uncontrolled on metformin alone. Avandamet was first approved in 2002 and is available in four tablet strengths of rosiglitazone/metformin: 2 mg/500 mg, 4 mg/500 mg, 2 mg/1000 mg, and 4 mg/1000 mg. GSK also announced that there is no shortage of Avandamet now.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.